KOR

e-Article

Initial diagnosis of chronic myelogenous leukemia based on quantification of M- BCR status using droplet digital PCR.
Document Type
Article
Source
Analytical & Bioanalytical Chemistry. Feb2016, Vol. 408 Issue 4, p1079-1094. 16p.
Subject
*CHRONIC myeloid leukemia
*CHROMOSOMAL translocation
*POLYMERASE chain reaction
*HUMAN chromosomes
*PROTEIN-tyrosine kinases
*FLUORESCENCE in situ hybridization
*DIAGNOSIS
Language
ISSN
1618-2642
Abstract
Formed from a reciprocal translocation t(9:22)(q34;q11) of genetic material between the long arms of human chromosomes 9 and 22, the constitutively active breakpoint cluster region (BCR) Abelson 1 (ABL) tyrosine kinase BCR-ABL is known to be causative of chronic myelogenous leukemia (CML). In 98 % of CML patients harboring the t(9:22)(q34;q11) translocation, known as the Philadelphia chromosome, the chimeric BCR-ABL oncogene is created through cleavage of the BCR gene within its major breakpoint region (M- BCR) and breakage of the ABL gene within a 100-kbp region downstream of exon 2a. Clinical detection of the fused BCR-ABL oncogene currently relies on direct visualization by fluorescence in situ hybridization (FISH), a relatively tedious assay that typically offers a detection limit of ca. 2 %. Here, we describe a novel assay that uses droplet digital PCR (ddPCR) technology to reliably measure M- BCR status and the presence of BCR-ABL. When applied to cell-line models of CML, the assay accurately quantifies BCR-ABL frequency to a detection limit of 0.25 %. It therefore offers improved specificity relative to FISH, and may allow identification of variant translocation patterns, including derivative chromosome 9 deletions. [Figure not available: see fulltext.] [ABSTRACT FROM AUTHOR]